IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Federico Cappuzzo(Ospedale di Livorno), Howard West(Vyne Therapeutics (United States)), A. Sandler, Venice Archer(AstraZeneca (United Kingdom)), Hans‐Georg Kopp(Robert Bosch Hospital), Henry Jacob Conter(William Osler Health System), Achim Rittmeyer(Unknown), Tania Ochi Lohmann(Roche (Switzerland)), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alona Zer(Rambam Health Care Campus), Davey B. Daniel(Tennessee Oncology), Maen Hussein(Sarah Cannon), L. Wang, Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Wei‐Hsin Lin(National Taiwan University Hospital), Michael McCleod(Sarah Cannon), A. Sadiq(Fort Wayne Medical Institute), Marcin Kowanetz, Tarek Mekhail(AdventHealth Orlando), Steve McCune(Northwest Behavioral Medicine)
Cited by 58
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k